Cianna Medical, an Aliso Viejo, CA-based breast brachytherapy company, has completed a $12m Series B funding round.
The round was led by Novo Ventures, Novo A/S ($8m), with participation from existing investors Fog City Fund, Emergent Medical Partners, and Saints Capital.
The company intends to use the funds to expand sales and marketing programs for its SAVI® breast brachytherapy applicator, a multicatheter device that provides accelerated partial breast irradiation (APBI), in the U.S. and internationally (to watch how the SAVI® Applicator works, click here http://www.ciannamedical.com/for_women/savi_anim.htm). In addition, the capital will allow the company to develop new products that are connected to its core business in radiation oncology and surgery.
Led by President and CEO Jill Anderson, Cianna is continuing to experience expedite growth following adoption of the SAVI device by hundreds of breast cancer treatment facilities across the country.
Heath Lukatch, PhD, a partner in Novo Ventures, and Tiba Aynechi, PhD, a Principal in Novo Ventures, Novo A/S, have joined Cianna Medical’s Board of Directors, whose other members include:
- Nancy Olson, Managing Partner of Fog City Fund;
- Zack Scott, MD, a Vice President of Saints Capital;
- Paul McCormick, former President and CEO of Endologix;
- Steven L. Gex, Chairman of Cianna Medical; and
- Jill Anderson.